Key result
M-TEER is linked to ~41% higher 12-month mortality vs surgery.
Why the study?
While surgery remains the standard treatment for severe mitral regurgitation, growing evidence highlights the potential role of percutaneous edge-to-edge repair, prompting a comparison of 12-month all-cause mortality between both approaches.
Does mitral valve percutaneous edge-to-edge repair (M-TEER) reduce 12-month all-cause mortality compared to surgical intervention in patients with severe mitral regurgitation?
Population
1,782 patients with MR across 2 RCTs and 3 observational studies
Comparison
M-TEER vs surgical intervention (SMVI)
Design
Inverse variance random-effects meta-analysis
Follow-up
12 months
Authors
Loading...
Supports limiting M-TEER to prohibitive surgical risk; confirms surgical superiority for 12-month mortality in operable severe MR.
Meta-Analysis (n=1,782)
Yes
Does mitral valve percutaneous edge-to-edge repair (M-TEER) reduce 12-month all-cause mortality compared to surgical intervention in patients with severe mitral regurgitation?
Effect estimate: RR 1.41 (95% CI 1.11-1.81)
Surgical intervention for severe mitral regurgitation is associated with lower 12-month all-cause mortality and lower rates of residual severe MR compared to M-TEER, reinforcing that M-TEER should be reserved for patients with prohibitive surgical risk.
Mata et al. (2026) conducted a meta-analysis in Mitral valve regurgitation (n=1,782). Mitral valve transcatheter edge-to-edge repair (M-TEER) vs. Surgical mitral valve intervention (SMVI) was evaluated on All-cause mortality at 12 months (RR 1.41, 95% CI 1.11-1.81). Mitral transcatheter edge-to-edge repair was associated with a significantly higher risk of all-cause mortality at 12 months compared to surgical intervention (RR 1.41).